Gene Therapy Is Booming, But How Will We Manage The Costs? – Forbes
Forbes |
Gene Therapy Is Booming, But How Will We Manage The Costs?
Forbes Bluebird has a while to go before it has to grapple with pricing, though it did make headlines in October, when it published results from a small trial of its gene therapy to treat the brain disease adrenoleukodystrophy (ALD). In a phase 2/3 trial, 15 … |
